Most people can keep taking a GLP-1 medication before elective surgery. That is the position of multi-society guidance released in October 2024 by anesthesiology, gastroenterology and bariatric surgery groups. The exceptions matter, though. If you have nausea, vomiting or bloating, or you recently started or raised your dose, your team may add a liquid diet, change the anesthesia plan or postpone the procedure. Never decide this alone. Tell your surgeon and anesthesiologist exactly what you take, the dose and the day of your last injection.
Semaglutide and tirzepatide work in part by slowing how quickly the stomach empties. That helps you feel full longer, which is one reason they work for weight loss. It also means food or fluid can remain in the stomach longer than the usual fasting window assumes.
The risk is pulmonary aspiration. Under general anesthesia or deep sedation, your protective reflexes are reduced. If stomach contents come up and reach the lungs, it can cause serious complications. The American Society of Anesthesiologists describes this as the main anesthetic concern with these drugs.
The FDA labeling for tirzepatide products now carries a warning about pulmonary aspiration during general anesthesia or deep sedation. The label notes there are postmarketing reports of aspiration in people who followed standard fasting rules but still had residual stomach contents. Those reports are why anesthesia teams ask about GLP-1 use at every pre-op visit.
For a deeper look at the mechanism, see our explainer on how GLP-1 medications affect gastric emptying.
In June 2023 the ASA issued consensus-based guidance that recommended holding the drug before elective procedures: the day of surgery for daily dosing and one week ahead for weekly dosing. Many hospital handouts still reflect that rule, which is why you may see conflicting instructions online.
The October 2024 multi-society guidance shifted the approach. It was written by the ASA together with the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery and other groups. Their reasoning, in short:
The FDA label adds a counterweight: available data are not sufficient to set a required stopping period or fasting change, so the decision is shared between you and your clinicians. Some institutions still publish stricter rules than the national guidance, and your hospital’s protocol is the one you will actually be held to.
The guidance sorts patients by how likely they are to have delayed stomach emptying. Here is how that plays out in practice.
| Your situation | What the guidance points toward |
|---|---|
| Stable dose, no GI symptoms, elective procedure | Often continue the medication as usual |
| Higher dose or other factors that raise GI risk | Possible 24-hour liquid-only diet before the procedure |
| Started or increased dose in the past 4 to 8 weeks | Higher risk; elective surgery is generally deferred until this phase passes |
| Nausea, vomiting, abdominal pain or bloating now | Delay elective surgery until symptoms fully resolve |
| Unsure of stomach status on the day | Full-stomach precautions, a stomach ultrasound or postponement |
The multi-society release describes the liquid diet, an adjusted anesthesia plan and point-of-care ultrasound as the tools for highest-risk patients, and delay in rare cases when risk is expected to fall. The ASA patient guidance says patients in the early escalation phase, roughly the first 4 to 8 weeks of dose increases, are more susceptible and should generally defer elective surgery until it is over.
Gastric ultrasound lets an anesthesiologist look at your stomach in real time and see whether it holds solid or complex contents or is empty. The Anesthesia Patient Safety Foundation has discussed it in the context of case reports of retained solid gastric contents in patients on semaglutide. If you did not follow your fasting instructions, or your stomach status is unclear, the team has two main options: use full-stomach precautions that change how general anesthesia is given, or postpone. According to the ASA, these precautions apply to general anesthesia, not to lighter sedation.
The practical lesson: if you vomited the night before, felt unusually full or ate something you were told to skip, say so. A postponed procedure is an inconvenience. Aspiration is an emergency.
People search for each drug by name, so here is the plain answer. The guidance addresses the GLP-1 receptor agonist class as a whole, and the FDA tirzepatide label carries the aspiration warning. The thinking applies to both semaglutide and tirzepatide, and to weekly injections as well as daily or oral forms.
What differs is your own situation: dose, how long you have been on it, and how you feel. Someone on week three of tirzepatide with morning nausea is in a different position from someone on a stable maintenance dose for a year. Your pre-op team will ask which drug, what dose and when you last took it, so keep that written down. If your provider adjusts your schedule, our guide to stopping GLP-1 treatment safely covers what to expect when doses are paused.
Colonoscopy and upper endoscopy are common reasons people ask this question. These procedures often use sedation, and some require a clear-liquid diet and laxative prep beforehand, which can feel rough if your GLP-1 already slows digestion or causes constipation. The multi-society guidance was co-developed with the American Gastroenterological Association, so GI teams are familiar with it.
We cannot tell you whether to hold your dose for a specific scope. Ask the endoscopy unit directly, and mention your GLP-1 when you schedule, not at check-in. If constipation is already an issue, our piece on GLP-1 constipation relief offers general background to discuss with your clinician before prep day. Fasting also has its own wrinkles on these drugs: see fasting with semaglutide.
If you have diabetes, also ask how your blood sugar will be managed during any pause. That is a question for the clinician who treats your diabetes, because stopping a drug can change your glucose control.
A related question is whether GLP-1s have a place after surgery such as gastric bypass or sleeve gastrectomy. Weight regain happens: one clinical review notes that around 20% to 30% of patients have suboptimal weight loss or significant regain after bariatric procedures, and that GLP-1s are being used as a treatment option in that group.
The evidence is still developing, and the labels are cautious. Eli Lilly states that tirzepatide has not been studied in people who have undergone any type of bariatric surgery, so any use there is a clinical judgment. Researchers are investigating it: a pilot trial called GRABS is testing tirzepatide in people with persistent obesity 12 months after Roux-en-Y gastric bypass.
After bariatric surgery your anatomy, nutrition needs and absorption differ. Dosing, protein targets and vitamin monitoring should be directed by your bariatric team together with whoever prescribes the medication. If you are considering a GLP-1 after a bypass, bring that conversation to your surgeon first.
We see the same pattern from patients who contact us before a procedure: they found two articles saying opposite things and do not know which to trust. Both were probably right for their date. The advice moved from a blanket pause to individual risk assessment, and that is a good change, because it recognizes that your medication, your dose and your symptoms matter.
Our view is simple. First, your anesthesia team owns the pre-op decision, and our job is to give them accurate information about what you take. Second, timing is within your control: avoid scheduling an elective procedure during a dose escalation if you can, and tell us before you book one. Third, a pause is not a failure. Many people worry that stopping for a procedure undoes their progress. A short interruption is manageable with your prescriber’s guidance, and restarting is a planned step.
Our program pairs prescription treatment with a physician-reviewed health questionnaire, ongoing virtual support and attention to strength and lifestyle habits that help preserve lean muscle. Recovery from surgery is a good time to lean on that. If you have an upcoming procedure, message our team early so your prescriber can coordinate with your surgical team.
— Eric
If you are planning surgery and also thinking about starting a GLP-1, timing matters, because the early weeks of treatment carry the higher aspiration risk described above. Discuss your surgery date with a clinician before you begin.
Oak Longevity offers online physician-reviewed access to semaglutide from $119 per month and tirzepatide from $185 per month, with support from our team throughout. You can see all options on our weight loss page. For general background first, read our guide to GLP-1 medications explained.
Not automatically. The 2024 multi-society guidance says most patients at low risk for delayed stomach emptying can continue, while higher-risk patients may need a liquid diet or a changed anesthesia plan. Your hospital may still have its own rule, so follow the written instructions from your surgical and anesthesia team.
The same reasoning applies. The FDA label warns about aspiration under general anesthesia or deep sedation but does not set a required stopping period. Your clinicians decide based on your dose, time on treatment and symptoms.
That depends on your endoscopy unit and your own risk. Tell them you use a GLP-1 when you book, and ask whether to take or skip your dose and how to handle the liquid prep. Do not guess.
Some clinicians prescribe them for weight regain after bariatric surgery, but the manufacturer notes tirzepatide has not been studied in this group. Ask your bariatric team, who know your anatomy and nutrition needs.
Tell them as soon as you remember, even on the day of surgery. They can use full-stomach precautions or a stomach ultrasound, or postpone, which is safer than proceeding unaware.
